The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.
 
Eva Muñoz Couselo
Honoraria - BMS; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; MSD; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Aventis; Takeda
Research Funding - Amgen (Inst)
 
Laurent Mortier
Honoraria - Bms france; MSD Oncology; Novartis; Sun pharma
Consulting or Advisory Role - BMS GmbH & Co. KG; Novartis; Sun Pharma
Research Funding - MSD Oncology (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech; Roche/Genentech
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma; Ultimovacs
Speakers' Bureau - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Delcath Systems; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Delcath Systems; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Research Funding - Almirall Hermal GmbH (Inst); Amgen (Inst); kyowa (Inst); Merck Serono (Inst); Regeneron (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pierre Fabre; Sun Pharma
 
Osama Roshdy
No Relationships to Disclose
 
Rene Lazaro Gonzalez Mendoza
No Relationships to Disclose
 
Jacob Schachter
No Relationships to Disclose
 
Ana Maria Arance
Consulting or Advisory Role - BioNTech SE; BMS; MSD; Novartis; Pierre Fabre; Roche
Speakers' Bureau - BMS; MSD; Novartis; Pierre Fabre; Roche
Research Funding - BioNTech SE (Inst); BMS (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Florent Grange
Honoraria - BMS Brazil
Consulting or Advisory Role - BMS Brazil
Travel, Accommodations, Expenses - BMS Brazil
 
Nicolas Meyer
Honoraria - Abbvie; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Janssen; Pierre Fabre
 
Abhishek Jagdish Joshi
Honoraria - Ipsen
Consulting or Advisory Role - Amgen; Merck Sharp & Dohme; Roche
Speakers' Bureau - Merck; Novartis; Roche
 
Salem Billan
Honoraria - MSD
Travel, Accommodations, Expenses - MSD
 
Sven Erik Ojavee
Employment - Merck
 
Jianda Yuan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Burak Gumuscu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Åse Bratland
Honoraria - Bristol Myers Squibb; Merck Serono; MSD Oncology; Sanofi
Research Funding - Britol Myers Squibb (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - MSD Oncology